Orchestra BioMed Holdings, Inc. splits its revenue into 2 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Partnership Revenue at $32.9 million, 98% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
|---|---|---|---|---|---|---|
| Revenue |
32
|
33
|
3
|
3
|
—
|
—
|
| Partnership Revenue |
—
|
33
+1539.5%
share 98.2%
|
2
-4.8%
share 76.0%
|
2
-26.4%
share 76.3%
|
3
|
—
|
| Product |
—
|
1
-3.5%
share 1.8%
|
1
-3.2%
share 24.0%
|
1
-2.5%
share 23.7%
|
1
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- OBIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New Hope, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1814114
- Former names
- Health Sciences Acquisitions Corp 2 (until Jan 26, 2023)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.